GH Research (GHRS) Cash from Operations (2020 - 2025)
GH Research (GHRS) posted quarterly Cash from Operations of 12330000.0 for Q4 2025, down 18.04% year-over-year from 15043118.43 in Q4 2024, and up 9.88% quarter-over-quarter from 13682000.0 in Q3 2025.
GH Research (GHRS) Cash from Operations (2020 - 2025) Analysis & Trends
GH Research's Cash from Operations history runs 6 years deep, the most recent figure standing at 12330000.0 for Q4 2025.
- In Q4 2025, Cash from Operations fell 18.04% year-over-year to 12330000.0; the TTM figure through Dec 2025 stood at 43552000.0 (down 3.0% YoY), while the FY2025 annual figure was 43552000.0, down 3.0% from the prior year.
- Cash from Operations for Q4 2025 stood at 12330000.0, up from 13682000.0 in the prior quarter.
- The five-year high for Cash from Operations was 1087000.0 in Q1 2021, with the low at 13682000.0 in Q3 2025.
- The 5-year median for Cash from Operations is 8770000.0 (2025), against an average of 8238400.0.
- The sharpest annual moves came in 2021 and 2022: Cash from Operations sank 11864.94% in 2021, then advanced 12.68% in 2022.
- GH Research's Cash from Operations stood at 3758000.0 in 2021, then sank by 95.45% to 7345000.0 in 2022, then plunged by 59.56% to 11720000.0 in 2023, then rose by 10.87% to 10446000.0 in 2024, then fell by 18.04% to 12330000.0 in 2025.
- Business Quant data shows GHRS's Cash from Operations at 12330000.0 in Q4 2025, 13682000.0 in Q3 2025, and 8967000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | GH Research | 2.02 Bn | 1.68 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -12.33 Mn |
| Dec 31, 2025 | -12.33 Mn |
| Sep 30, 2025 | -13.68 Mn |
| Sep 30, 2025 | -13.68 Mn |
| Jun 30, 2025 | -8.97 Mn |
| Jun 30, 2025 | -8.97 Mn |
| Mar 31, 2025 | -8.57 Mn |
| Mar 31, 2025 | -8.57 Mn |
| Dec 31, 2024 | -10.45 Mn |
| Dec 31, 2024 | -10.45 Mn |
| Sep 30, 2024 | -12.31 Mn |
| Sep 30, 2024 | -12.31 Mn |
| Jun 30, 2024 | -9.94 Mn |
| Jun 30, 2024 | -9.94 Mn |
| Mar 31, 2024 | -9.60 Mn |
| Mar 31, 2024 | -9.60 Mn |
| Dec 31, 2023 | -11.72 Mn |
| Dec 31, 2023 | -11.72 Mn |
| Sep 30, 2023 | -10.34 Mn |
| Sep 30, 2023 | -10.34 Mn |